FOLH1 and Familial prostate cancer: On the other hand, as discussed at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, we understand that the novel treatment of 177Lu-PSMA-617 radioligand therapy for metastatic prostate cancer is one of the most attractive candidates (56, 57).